VANCOUVER, BRITISH COLUMBIA, Dec. 23, 2009 (Marketwire) -- Pyng Medical Corp. (TSX VENTURE:PYT) today released its audited fiscal 2009 results for the year ended September 30, 2009. Pyng reported fourth quarter sales were $1,718,272 and total annual sales of $6,026,177. Net loss before tax for the year was $62,904 and after tax was $246,904.
Cost of sales for the fourth quarter of 2009 was $416,034 providing a gross margin of $1,302,238 or 76%. On a year to date basis, cost of sales was $1,685,547 providing a gross margin of $4,340,630 or 72%. Total cash operating expenses for the forth quarter of 2009 increased to $1,056,369 compared to $912,167 for the fourth quarter of fiscal 2008. On a year to date basis, total cash operating expenses for fiscal 2009 increased to $3,959,236 compared to $3,265,879 for fiscal 2008.
Full audited financial results for fiscal 2008 are available on SEDAR at www.sedar.com.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front- line critical care personnel. Creators of the FAST1(R) Intraosseous Infusion System, Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company's proprietary FAST1(R), the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.